Rep. Gilbert Cisneros (D-CA) Buys LGND Stock

Gilbert Cisneros Continues Trading Activity

Representative Gilbert Cisneros, a Democrat representing California's 31st district, purchased shares of Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) on May 29, 2026. According to a periodic transaction report filed on June 9, 2026, the trade was valued in a range between $1,001 and $15,000.

This purchase fits a broader pattern of recent activity for Cisneros. Earlier in the same month, he disclosed similar trades in Sensata Technologies and STERIS plc. These disclosures are part of the regular financial reports required of members of Congress, which provide a window into their investment moves after they occur.

Ligand Pharmaceuticals Stock Momentum

Ligand Pharmaceuticals shares were recently priced at $312.50. The stock has been on a steady path upward, trading far above its 200-day moving average of $236.48. While it is currently sitting near its 52-week high of $326.63, it remains well off its 52-week low of $163.45.

Investors often look at the P/E ratio, which compares a company's share price to its earnings, to see how it is valued. Ligand has a P/E ratio of 29.84. When looking at expected future earnings, its forward P/E is slightly lower at 24.30. The company's market value stands at roughly $5.78 billion.

Recent Earnings Growth

In its most recent financial update, Ligand reported revenue of $290.54 million. This represents a 33.7% increase in revenue growth compared to the prior period. The company is also showing strong profitability, with a net margin of 67.88% and a return on equity of 21.96%. Shareholders can look for the next set of financial results when the company reports again on November 5, 2026.

Insider Buying and Selling at Ligand Pharmaceuticals Incorporated

Several company insiders have been active in the market alongside the recent congressional trade. On June 16, 2026, Stephen Sabba exercised options to buy 2,145 shares at $66.13 and sold the same number of shares on the same day at an average price of $254.00, a transaction worth about $544,830. Earlier, on June 12, 2026, Jason Haas also exercised options for 4,000 shares at a price of $51.56. These types of transactions are common as executives manage their compensation and equity stakes.

Analysts Set New Price Targets

Wall Street firms have been largely positive on Ligand's prospects. On September 25, 2026, Barclays initiated coverage with an Overweight rating and a $345.00 price target. This followed a move by Citigroup on September 23, 2026, which maintained a Buy rating and raised its target from $390.00 to $397.00. HC Wainwright & Co. also reiterated a Buy rating on September 24, 2026, with a $358.00 target. Currently, 11 analysts cover the stock with an average price target of $342.82.

About Ligand Pharmaceuticals

Ligand Pharmaceuticals is a biotechnology company that focuses on developing and licensing assets for a wide range of medical needs. Instead of just making one drug, it partners with other firms to bring treatments to market for things like diabetes, pneumonia, and various cancers. The company's business model relies on royalties and milestone payments from these partnerships.

What's Ahead for Ligand Pharmaceuticals Incorporated

Investors will likely watch the November earnings report to see if the company can maintain its double-digit revenue growth. While the purchase by Representative Cisneros shows recent interest from a lawmaker, these filings are backward-looking and do not represent a real-time view of his portfolio. The stock's performance relative to analyst targets will also be a key factor for the remainder of the year.